

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/22879>

Please be advised that this information was generated on 2019-02-21 and may be subject to change.

Reduction of Epidermal Abnormalities and Inflammatory Changes in Psoriatic Plaques During Treatment With Vitamin D₃ Analogs

Peter C. M. van de Kerkhof

Department of Dermatology, University of Nijmegen, Nijmegen, The Netherlands

Vitamin D₃ analogs interfere with various aspects of epidermal growth, inflammation, and cellular differentiation. Most data are derived from *in vitro* studies. In the present review, the *in vivo* effects of vitamin D₃ analogues on the psoriatic plaque are discussed. Calcipotriol, tacalcitol, and calcitriol in ointment modulate aspects of epidermal growth, differentiation, and inflammation. Immunohistochemical studies suggest that the inflammatory changes might be more expressed after treatment with calcitriol and tacalcitol. Flow cytometric quantification of the percentage of cells in S_G₂M phase and of keratin 10-positive cells revealed that calcipotriol reduced both indices significantly during treatment of psoriatic plaques. Flow cytometric analysis of epidermal cell

suspensions using triple labeling for epidermal proliferation, expression of keratin 10, and vimentin permits a quantitative assessment of DNA synthesis selectively in the basal cells of the epidermis, an estimation of the distribution of the basal and suprabasal compartments, and a quantification of the distribution of mesenchymal and nonmesenchymal cells. Using this approach, the interference of tacalcitol with growth control of basal cells was demonstrated. Remarkably, re compartmentalization of basal and suprabasal cells and mesenchymal and nonmesenchymal cells proved to be inconspicuous during this treatment. *Key words: calcitriol/calcipotriol/tacalcitol. Journal of Investigative Dermatology Symposium Proceedings 1:78-81, 1996*

In the last decade, vitamin D₃ analogs have become an important approach in the treatment of psoriasis. Calcipotriol is available as a routine treatment in many countries (Binderup and Kragballe, 1992). In Japan, tacalcitol (1 α , 24-dihydroxyvitamin D₃) is a first line of treatment for psoriasis (Nishinura *et al*, 1993). Calcitriol (1 α , 25-dihydroxyvitamin D₃) is the naturally occurring, active vitamin D₃ and has been investigated with respect to its antipsoriatic efficacy and safety (Langner *et al*, 1992).

The aim of the present review is to evaluate the actions of calcipotriol, tacalcitol, and calcitriol on psoriatic skin during topical treatment.

VITAMIN D₃ ANALOGS INHIBIT EPIDERMAL PROLIFERATION, ENHANCE NORMAL KERATINIZATION, AND MODULATE INFLAMMATION

Calcipotriol, calcitriol, and tacalcitol bind to the vitamin D receptor (VDR), and the complex binds to vitamin D response elements within promoter regions of vitamin D response genes (Ozone *et al*, 1991). VDR belongs to the steroid receptor superfamily together with the receptors for retinoids, estrogen, thyroxine, and glucocorticosteroids. Evidence is accumulating that the receptors within this family do not act in isolation, but interact. As such, the heterodimer formation of VDR and the RXR- α receptor is important because

the heterodimer exerts a more potent binding with vitamin D response elements compared with VDR alone (Kliewer *et al*, 1992).

In addition to these nuclear mechanisms, vitamin D₃ analogs have a direct effect on calcium entry. Indeed at physiologic concentrations, calcitriol has been shown to enhance calcium entry into keratinocytes (Brittner *et al*, 1991).

Either via nuclear mechanisms or by increased entry of calcium into the cell, vitamin D₃ enhances the production of inositol trisphosphate and 1,2-diacylglycerol (MacLaughlin *et al*, 1990). Another important effect of vitamin D₃ analogs in cell signaling is the translocation of protein kinase C from the cytosolic to the membrane position (Yada *et al*, 1989).

At the cellular level, vitamin D₃ analogs have been shown to inhibit proliferation of keratinocytes and to enhance cornified envelope formation (Binderup and Bramm, 1988; Kragballe and Wildfang, 1990). At the molecular level, vitamin D₃ analogs enhance transglutaminase activity, which is a crucial enzyme for cornified envelope formation (Hosomi *et al*, 1983; Lee *et al*, 1989; Matsunaga *et al*, 1990). In contrast to retinoids, vitamin D₃ analogs do not modulate the transcription of keratin genes. These compounds specifically interfere with the last step of differentiation (Regnier and Darmon, 1991).

Vitamin D₃ analogs have diverse effects on inflammation control. Interleukin (IL)-1-induced T-lymphocyte proliferation is inhibited by active vitamin D₃ (Tsoukas *et al*, 1984). Production of IL-2 and IL-6 by T lymphocytes and accumulation of mRNA for IL-2, interferon- γ , and granulocyte-macrophage colony-stimulating factor increase in the T lymphocyte after incubation with calcitriol (Tsoukas *et al*, 1984; Gupta *et al*, 1989; Hustmyer *et al*, 1991; Lemire, 1992). Macrophages are activated by calcitriol, and

Reprint requests to: Dr. Peter C. M. van de Kerkhof, Department of Dermatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

Abbreviations: TP₃, TO-PRO-3 iodide; VDR, vitamin D receptor.

Table I. Monoclonal Antibodies Used for the Immunohistochemical Assessments^a

Cell Biologic Feature	Antibody
Recruitment of cycling cells	Ki-67
Keratin 16 expression	K _s 8.12
Involucrin	Mon-150
Filaggrin	Anti-filaggrin (BT 576)
Transglutaminase I	Anti-TG-ase I (IgG _{2a})
Pan T cells	T 11
Polymorphonuclear leukocytes	Anti-elastase
Monocytes (CD14)	WT 14
Langerhans cells	OKT 6

^a The immunohistochemical procedures have been described before (de Jong and van de Kerkhof, 1991; Gerritsen *et al*, 1993, 1994, 1995).

the interferon-gamma-induced expression of human leukocyte antigen-D on keratinocytes is inhibited by calcitriol (Lehman and Gray, 1984; Petrini *et al*, 1991; Tone *et al*, 1991; Oberg *et al*, 1993). Arachidonic acid release and migration of polymorphonuclear leukocytes (PMN) are inhibited by vitamin D₃ analogs (Tanaka *et al*, 1988).

VITAMIN D₃ ANALOGS ARE CLINICALLY EFFECTIVE IN CHRONIC PLAQUE PSORIASIS, PUSTULAR PSORIASIS, AND ICHTHYOSSES

Based on the *in vitro* observations, it is feasible that calcipotriol, tacalcitol, and calcitriol are effective in skin disorders characterized by epidermal hyperproliferation, abnormal keratinization, and inflammation. Indeed, the therapeutic efficacy of active vitamin D₃ is not restricted to chronic plaque psoriasis, but also affects pustular psoriasis (Berth Jones *et al*, 1992). Active vitamin D₃ has proved effective in some disorders of keratinization (Kragballe *et al*, 1995).

REDUCTION OF IMMUNOHISTOCHEMICAL CHANGES DURING TREATMENT

Three clinical studies were carried out in patients with chronic plaque psoriasis to assess the effect of twice-daily applications of calcipotriol (50 µg/g) in ointment, once-daily applications of tacalcitol (4 µg/g) in ointment, and twice-daily applications of calcitriol (3 µg/g) in ointment (de Jong *et al*, 1991; Gerritsen *et al*, 1993, 1994, 1995). In previous dose-response studies, these concentrations proved to provide optimal clinical efficacy. In total, eight patients were included for treatment with calcipotriol, ten patients for treatment with calcitriol, and ten patients for treatment with tacalcitol in ointment. Before treatment and at various times, biopsy specimens were taken and processed for immunohistochemical assessment.

The immunohistochemical methods have been described before (de Jong *et al*, 1991; Gerritsen *et al*, 1993). In brief, samples were snap-frozen in liquid nitrogen, and consecutive sections were cut. Epidermal growth, differentiation, and inflammation characteristics were analyzed using an indirect peroxidase technique. Table I summarizes the monoclonal antibodies used in the studies.

Although the concentrations of active vitamin D₃ analogs used in the treatments were different, the clinical improvement was comparable. Approximately a 50% reduction of the psoriasis area severity index was achieved for all three analogs (Gerritsen *et al*, 1994, 1995).

The maximum observation period for calcipotriol ointment was 12 wk (de Jong *et al*, 1991). After 2 wk of treatment with calcipotriol ointment, a significant decrease in the number of cycling epidermal cells (Ki-67-positive nuclei) was observed. During the subsequent observation period, the number of Ki-67-positive nuclei showed only a modest reduction beyond that reached after 2 wk of treatment. Keratin 16 (K_s 8.12 binding of the suprabasal compartment of the epidermis) tended to decrease between 4 and 8 wk of treatment. After 1 wk of treatment, only small microabscesses of PMN were observed, and after 4 wk of treatment, no microabscesses were observed at all. The accumula-

tion of T cells showed only a small reduction in the 12-wk treatment period, reaching borderline significance after 4 wk. The accumulation of monocytes and macrophages did not show a significant modulation during calcipotriol treatment.

The maximum observation period for calcitriol treatment was 4 wk (Gerritsen *et al*, 1993). During this treatment period, the maximum reduction of the number of Ki-67-positive epidermal nuclei was observed after 4 wk of treatment. In this study, the numbers of involucrin-positive and transglutaminase-I-positive cells decreased, and the number of filaggrin-positive cells increased. Pan T cells and PMN decreased markedly during the observation period.

The maximum observation period for tacalcitol treatment was 8 wk (Gerritsen *et al*, 1994, 1995). During this interval, the numbers of Ki-67-positive nuclei and the involucrin-, keratin-16-, and transglutaminase-positive cell layers had diminished substantially, whereas the number of filaggrin-positive cell layers had increased. Tacalcitol had a remarkable effect on the number of PMN, T cells, and monocytes in the dermis and epidermis of the psoriatic lesion. In contrast, the ointment without tacalcitol had no significant effect on these markers, apart from a reduction in the number of Ki-67-positive nuclei.

These immunohistochemical studies suggest that the three vitamin D₃ analogs have an effect on epidermal growth, keratinization, and cutaneous inflammation (Table II). The reduction of the inflammatory infiltrate was most pronounced after treatment with tacalcitol. Definitive conclusions on the relative potencies of these analogs require comparative studies.

In various centers, the *in vivo* effects of vitamin D₃ analogs have been studied. On the one hand, these studies suggest a reduction of keratin-16- and keratin-17-positive cells and normalization of keratin-5- and keratin-10-positive cells, with only modest changes of the immune system (Verburgh *et al*, 1989; Holland *et al*, 1990; Berth Jones *et al*, 1991; de Jong *et al*, 1991). One study suggested, however, that calcipotriol treatment causes a reduction of helper T cells with a relative persistence of epidermal phenomena (Malet *et al*, 1990). In another study, it was shown that calcipotriol treatment reduced IL-6 staining without altering tumor necrosis factor-α staining (Oxholm *et al*, 1989). Light and electron microscopic investigations showed that tacalcitol treatment induced a normal keratin pattern and the reappearance of normal keratohyalin granules (Ueda *et al*, 1989).

The general pattern of the immunohistochemical response is a pronounced reduction of epidermal proliferation and the accumulation of PMN. Other topical treatments such as corticosteroids (de Jong *et al*, 1995) and dithranol (de Jong and van de Kerkhof, 1992) were shown to have a similar *in vivo* response: the reduction of epidermal proliferation and the accumulation of PMN as a non-specific effect. The reduction of PMN, T cells, and monocytes,

Table II. Reduction of Epidermal Proliferation and Modulation of Keratinization and Inflammation During Treatment With Vitamin D₃ Analogs^a

	Calcipotriol (50 µg/g Twice Daily)	Calcitriol (3 µg/g Twice Daily)	Tacalcitol (4 µg/g Once Daily)
Ki-67	↓↓	↓↓	↓↓
Keratin 16	↓	ND	↓
Involucrin	ND	↓	↓
Filaggrin	ND	↑	↑
Transglutaminase	ND	↓	↓
Polymorphonuclear leukocytes	↓↓	↓↓	↓↓
Pan T cells	=/ ↓	↓	↓
Monocytes	=	ND	↓
Langerhans cells	=	ND	=

^a Quantification of the responses has been described before (de Jong and van de Kerkhof, 1991; Gerritsen *et al*, 1993, 1994, 1995). Abbreviations: =, no modulation; ↓, slight decrease after treatment; ↓↓, marked decrease after treatment; ↑, slight increase after treatment; ND, not done.

however, was relatively more expressed during treatment with calcitriol and tacalcitol than with calcipotriol.

The antiproliferative action and the inhibition of PMN functioning are observed both *in vitro* and *in vivo*. In contrast to the activation of monocytes *in vitro*, tacalcitol induced a reduction of the accumulation of monocytes in the psoriatic plaques. And in contrast to the substantial inhibition of T-cell functioning *in vitro*, these cells tended to persist during treatment with vitamin D₃ analogs. In contrast to enhancement of transglutaminase I activity *in vitro*, during treatment with vitamin D₃ analogs the number of transglutaminase-I-positive cell layers decreased.

To elucidate further the *in vivo* action profile of vitamin D₃ analogues, quantitative comparative studies are required.

FLOW CYTOMETRIC QUANTIFICATION OF EPIDERMAL CHANGES DURING TREATMENT

To quantify epidermal hyperproliferation in the psoriatic plaque before and during treatment with calcipotriol and betamethasone, flow cytometric assessment was carried out of DNA distribution and keratin 16 expression (de Mare *et al*, 1990). In this study, a group of 20 patients with chronic plaque psoriasis were treated twice daily with calcipotriol (50 µg/g) in ointment and betamethasone in ointment in a double-blind trial with a left-right comparison. Before treatment and after a treatment period of 6 wk, razor-blade biopsy specimens (0.5 mm thick, 4 mm in diameter) were taken from two lesions at both sides. Epidermal cell suspensions were prepared using a trypsinization procedure, as described previously (Bauer *et al*, 1980). To assess keratin 16 expression, we incubated the cell suspensions with the monoclonal antibody K_s 8.12 and fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG as second antibody (de Mare *et al*, 1990). Propidium iodide was added to measure relative DNA content per cell (de Mare *et al*, 1990). Five thousand cells of each sample were analyzed using an Ortho 50H flow cytometer equipped with a 5-W argon laser tuned at 488 nm. Both treatments induced similar reductions of these indices. The values, however, were still well above the normal ranges (percentage K_s 8.12 cells: 1.8 ± 1.0 [mean \pm SEM] [van Erp *et al*, 1989] and percentage cells in SG₂M phase: 4.0 ± 0.7 [Bauer *et al*, 1981]).

Although this approach permits quantification of proliferation characteristics in epidermal cells, the methodology is complicated by the fact that suprabasal cells and mesenchymal cells are not excluded from the assessment.

Recently, a new methodology was developed using a triple labeling approach. Per-cell DNA content was measured using the new DNA stain TO-PRO-3 iodide (TP3); anti-vimentin was used to identify all nonkeratinocytes (infiltrate cells and other mesenchymal cells); RKSE 60 staining was carried out to assess keratin 10 expression, which indicates whether a cell belongs to the suprabasal cell population. Cell suspensions were prepared as described before, and the staining procedures have been described previously (Bauer and Boezeman, 1983; van Hooijdonk *et al*, 1995). The second step of the indirect immunofluorescent staining was performed with monoclonal goat antibodies against mouse IgG₁ and IgG_{2a}, conjugated to phycoerythrin and fluorescein-isothiocyanate (FITC), to assess RKSE 60 binding and anti-vimentin binding, respectively. Phycoerythrin and FITC were excited with an air-cooled argon laser (633 nm), and TP₃ was excited with an HeNe laser (488 nm). After electron compensation for spectral overlap, which was minimal in the case of TP₃, fluorescence was measured using band-pass filters at 525 nm (green FITC), 575 nm (orange, phycoerythrin), and 675 nm (red, TP₃). The ratio of area to peak of the red signal was used to discriminate between doublets of diploid cells and real tetraploid cells (Bauer and Boezeman, 1983). After setting the appropriate gates with the Elite software percentages and with the aid of Multicycle software, the percentages of vimentin- and keratin-10-positive cells and the percentage of cells in SG₂M phase were calculated. From these data, the percentage of cells in SG₂M phase within the pure basal cell population was calculated.

In total, 20 patients participated in a left-right comparative study

between tacalcitol (4 µg/g) in ointment and the ointment base only (Glade *et al*, 1995). Applications were done once daily. Razor-blade biopsy specimens were taken before treatment and after 8 wk of treatment from two lesions at both sides. Cell suspensions were prepared, and triple-label flow cytometric assessment was carried out according to the methods described above. The sides treated with tacalcitol showed a mean reduction of the psoriasis area severity score of 48%. The psoriasis area severity score of the lesions treated with placebo ointment was decreased by 28%.

In the psoriatic lesions before tacalcitol treatment, the percentage of basal cells in SG₂M phase was $20.0 \pm 1.9\%$ (mean \pm SEM); after 8 wk of treatment, the percentage was reduced to $13.2 \pm 1.1\%$. This reduction was statistically significant ($p \leq 0.01$). At the placebo-treated sides, the pretreatment value was $17.8 \pm 1.8\%$, and the value after 8 wk of placebo treatment was $15.1 \pm 1.2\%$.

The pronounced reduction of this cell-cycle kinetic marker during tacalcitol treatment illustrates the potent effect of tacalcitol on epidermal hyperproliferation *in vivo*. Triple-label flow cytometry has proved to be an adequate tool to restrict the analysis of indices for epidermal proliferation to the basal cells, even within a population as heterogeneous and complex as the inflamed epidermis of the psoriatic lesion.

I would like to acknowledge the secretarial support of Mrs. T. van Son-Verstraeten.

REFERENCES

- Bauer FW, Boezeman JBM: Flow cytometric methods in human skin with respect to cell cycle kinetics. In: Wright NB, Camplejohn RS (eds.). *Psoriasis: Cell Proliferation*. Churchill Livingstone, Edinburgh, 1983, pp 104-116
- Bauer FW, Crombach NHCNM, Boezeman JBM, de Grood RM: Flow cytometry as a tool for the study of cell kinetics in skin. *Cell kinetic data in psoriasis. Br J Dermatol* 104:271-276, 1981
- Bauer FW, Crombach NHCNM, de Grood RM: Quantification of deviations of the epidermal DNA distributions in psoriasis and the effect of therapy. *Flow Cytometry* 4:377-381, 1980
- Berth Jones J, Bourke J, Bailey K, Graham Brown RAC, Hutchinson PE: Generalised pustular psoriasis: response to topical calcipotriol. *BMJ* 305:868-869, 1992
- Berth Jones J, Fletcher A, Hutchinson PE: Epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol. In: Norman AW, Bouillon R, Thomass M (eds.). *Vitamin D: Gene Regulation Structure Function Analysis, Clinical Applications*. De Gruyter, Berlin, 1991, pp 424-425
- Binderup L, Bramm E: Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation *in vitro* and on calcium metabolism *in vivo*. *Biochem Pharmacol* 37:889-895, 1988
- Binderup L, Kragballe K: Origin of the use of calcipotriol in psoriasis treatment. *Rev Contemp Pharmacother* 3:357-365, 1992
- Brittiner B, Blechen SS, MacNeil S: $1\alpha,25-(OH)_2$ -vitamin D₃ increases intracellular calcium in human keratinocytes. *Br J Dermatol* 124:230-235, 1991
- de Jong EMGJ, Ferrier C, Wauben-Penris PJJ, Korstanje C, van de Kerkhof PCM: Effects of topical treatment of Budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. *J Dermatol Sci* (in press)
- de Jong EMGJ, van de Kerkhof PCM: Short contact dithranol treatment of psoriasis, using a novel emulsifying ointment (Hermal-AW[®]): changes in clinical scores and in parameters for inflammation, proliferation, keratinization. *Eur J Dermatol* 2:552-558, 1992
- de Jong EMGJ, van de Kerkhof PCM: Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long term treatment with vitamin D₃ analogue MC 903: modulations and interrelations. *Br J Dermatol* 124:221-229, 1991
- de Jong EMGJ, van Vlijmen-Willems IMJJ, van Erp PEJ, Ramaekers FCS, van de Kerkhof PCM: Keratin 17: a useful marker in psoriatic therapies. *Arch Dermatol Res* 283:480-482, 1991
- de Mare S, de Jong EMGJ, van de Kerkhof PCM: DNA content and K_s 8.12 binding of the vitamin D₃ analogue MC 903 and betamethasone. *Br J Dermatol* 123:291-295, 1990
- Gerritsen MJP, Boezeman JBM, van Vlijmen-Willems IMJJ, van de Kerkhof PCM: The effect of tacalcitol ($1,24-(OH)_2$ -D₃) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo controlled, double blind study. *Br J Dermatol* 286:455-461, 1994
- Gerritsen MJP, Rulo HFC, van Vlijmen-Willems IMJJ, van Erp PEJ, van de Kerkhof PCM: Topical treatment with $1\alpha, 25$ -dihydroxy-cholecalciferol: a cell biological study. *Br J Dermatol* 128:666-673, 1993
- Gerritsen MJP, van Erp PEJ, van de Kerkhof PCM: Transglutaminase positive cells in psoriatic epidermis during treatment with calcitriol and tacalcitol. *Br J Dermatol* in press
- Glade CP, van Erp PEJ, van Hooijdonk CAEM, van de Kerkhof PCM: Topical treatment of psoriatic plaques with $1\alpha, 24$ -dihydroxy vitamin D₃: a multiparam-

- eter flow cytometrical analysis of epidermal growth, differentiation and inflammation. *Acta Derm Venereol (Stockh)* in press
- Gupta S, Fass O, Shimuzu M, Vayuvegula B: Potentiation of immunosuppressive effects of cyclosporin A by 1 α , 25-dihydroxy vitamin D₃. *Cell Immunol* 121:290-297, 1989
- Holland DB, Roberts SG, Russell A, Wood EJ, Cunliffe WJ: Changes in epidermal keratin levels during treatment of psoriasis with the topical vitamin D₃ analogue MC 903. *Br J Dermatol* 122:284, 1990
- Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T: Cultured mouse epidermal cells by 1 α , 25-dihydroxyvitamin D₃. *Endocrinology* 113:1950-1957, 1983
- Hustmyer FG, Benniger L, Manolagas SC: Comparison of the effects of 22-oxa-1,25(OH)₂D₃ and MC903 on the production of IL-6, gamma-IFN and T lymphocyte proliferation in peripheral blood mononuclear cells. *J Bone Miner Res* 6:S292-S298, 1991
- Kliwer SA, Umesono K, Mangelsdorf DJ, Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D₃ signalling. *Nature* 355:446-449, 1992
- Kragballe K, Steijlen PM, van de Kerkhof PCM, Esman J, Sørensen LH, Ibsen HH, Axelsen MB: Efficacy, tolerability and safety of calcipotriol ointment in disorders of keratinization. *Arch Dermatol* 131:556-560, 1995
- Kragballe K, Wildfang IL: Calcipotriol, MC 903, a novel vitamin D₃ analogue, stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. *Arch Dermatol Res* 282:164-167, 1990
- Langner A, Verjans H, Stapor V, Mol M, Frazykowska M: 1 α , 25-dihydroxy vitamin D₃ calcitriol ointment in psoriasis. *J Dermatol Treat* 3:177-184, 1992
- Lee SC, Ikai K, Ando Y, Imamura S: Effects of 1 alpha, 25-dihydroxy vitamin D₃ on the transglutaminase activity of transformed mouse epidermal cells in culture. *J Dermatol* 16:7-11, 1989
- Leman J Jr, Gray RW: Calcitriol, calcium and granulomatous disease. *N Engl J Med* 311:1115-1117, 1984
- Lemire JM: Immunomodulatory role of 1,25-dihydroxy vitamin D₃. *J Cell Biochem* 49:26-31, 1992
- MacLaughlin JA, Cantley LC, Holick MF: 1,25(OH)₂D₃ increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. *J Nutr Biochem* 1:81-87, 1990
- Malet RB, Coulson IH, Purkis PE: An immunohistochemical analysis of changes in the immune infiltrate and keratin expression in psoriasis treated with calcipotriol compared with betamethasone ointment. *Br J Dermatol* 123:837, 1990
- Matsunaga T, Yamamoto M, Mimura H: 1,24 (R)-dihydroxy vitamin D₃, a novel active form of vitamin D₃ with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. *J Dermatol* 17:135-142, 1990
- Nishinura M, Hori Y, Nishiyama S, Nakamizo Y: Topical 1 α , 24 (R)-dihydroxy vitamin D₃ for the treatment of psoriasis. Review of the literature. *Eur J Dermatol* 3:255-261, 1993
- Oberg F, Bolling J, Nilsson K: Functional antagonism between vitamin D₃ and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. *J Immunol* 150:3487-3495, 1993
- Oxholm A, Oxholm P, Staberg B, Bendtzen K: Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC903). *Acta Derm Venereol (Stockh)* 69:385-390, 1989
- Ozone K, Sone T, Pike JW: The genomic mechanism of action of 1,25-dihydroxy vitamin D₃. *J Bone Miner Res* 6:1021-1027, 1991
- Petrini M, Dastoli G, Valentini P, Mattii L, Trombi L, Testi R, Ambrosi F, Grossi B: Synergetic effects of alpha interferon and 1,25 dihydroxy vitamin D₃: preliminary evidence suggesting that interferon induces expression of the vitamin D receptor. *Haematologica* 76:467-471, 1991
- Regnier M, Darmon M: 1,25 Dihydroxy vitamin D₃ stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. *Differentiation* 47:173-188, 1991
- Tanaka Y, Kauck TM, Jubiz W: In vivo effects of 1,25-dihydroxy vitamin D₃ and minerals on the synthesis of leukotriene B₄ and 5-hydroxy eicosatetraenoic acid by rat peritoneal neutrophils. *Prostaglandins Leukot Essent Fatty Acids* 32:9-14, 1988
- Tone T, Eto H, Katsuoka K: Suppression of gamma-interferon induced HLA-D_r antigen expression on normal and transformed keratinocytes by 1 α , 25(OH)₂ vitamin D₃. *Nippon Hifuka Gakkai Zasshi* 101:519-525, 1991
- Tsoukas CD, Provodini DM, Manolagas SC: 1,25-dihydroxy vitamin D₃: a novel immunoregulatory hormone. *Science* 224:1438-1440, 1984
- Ueda K, Suzuki H, Nakagawa S, Kawahara K: Light microscope and electron microscope studies on the guinea pig skin on the lesions of psoriasis vulgaris after topical application of 1 α , 24-dihydroxy vitamin D₃. *Acta Dermatol (Kyoto)* 84:341-358, 1989
- van Erp PEJ, Rijzewijk JJ, Boezeman JBM: Flow cytometric analysis of epidermal subpopulations from normal and psoriatic skin using monoclonal antibodies against intermediate filaments. *Am J Pathol* 135:865-870, 1989
- van Hooijdonk CAEM, Glade CP, van Erp PEJ: TO-PRO-3 iodide, a novel HeNe laser-excitable DNA stain as an alternative for propidium iodide in multiparameter flow cytometry. *Cytometry* in press
- Verburgh CA, Nieboer CA: Local application of vitamin D derivative MC903 in psoriasis: influence on cellular infiltrate, Langerhans cells and keratinocyte markers. *J Invest Dermatol* 93:310, 1989
- Yada Y, Ozeki T, Meguro S: Signal transduction in the onset of terminal keratinocyte differentiation induced by 1,25-dihydroxy vitamin D₃: role of protein kinase C translocation. *Biochem Biophys Res Commun* 163:1517-1522, 1989